Dupilumab (Dupixent; Sanofi/Regeneron) received FDA approval on June 7, 2022, for children aged 6 months to 5 years with 

. Its utility, however, may extend well beyond labeled indications.

, Ilona Frieden, MD, professor of dermatology and pediatrics at the University of California, San Francisco, outlined a growing body of evidence supporting off-label use of dupilumab across a range of pruritic and inflammatory pediatric skin conditions.

 In the following Q&A, Frieden discusses which conditions are generating the most interest, how she weighs the risk-benefit calculus in pediatric patients, and why safety data borrowed from other specialties can help guide decision-making.

Can you walk us through what you're covering on the expanding use of dupilumab?

 With dupilumab, I really talk about the fact that it's FDA-approved for atopic dermatitis, down to just a few months of age. It's also approved for children age 12 and over for chronic spontaneous urticaria.

We see children who have prurigo nodularis as a disease manifestation, but it's only approved for adults with prurigo nodularis. Certainly, we use drugs commonly off label, and so we would consider it for that.

There’s a whole list of expanded indications that have been reported in small case series or sometimes larger case series for things that are itchy for other reasons. There's a rare form of epidermolysis bullosa that's very itchy—it's really life-transforming for that. It's called EB pruriginosa, which stands for pruritic EB. There's also a form of ichthyosis, what's now called epidermal differentiation disorder, [and] Netherton syndrome, another rare disease [with] severe pruritus, where it can be transformative.

HCPLive: Can you provide examples of which conditions use the expanded use of dupilumab?

One is a disease called solid facial edema, which is considered to be possibly a form of lymphatic disruption, often due to acne on the face. It's a very rare disease, but there's a report in the literature from last year, and I show a very dramatic case of a patient of ours where it was truly incredibly effective.

We don't really know why, because dupilumab has a very narrow spectrum as an antagonist of IL-4 and 13. But there's a lot we don't know about biology, and anything that has some degree of inflammation or itch is certainly something we can consider. We know it's a very safe medication in children because it's been used in tens of thousands of pediatric patients at this point for atopic dermatitis.

I also show an example of older patients who have chronic irritation in the groin area, sometimes from leaking of urine. These are children who have an increased propensity for accidents, and sometimes they have developmental disabilities, so they don't control their bowel and bladder very well, and sometimes they're in diapers. Anecdotally, we've seen that some of those patients improve a lot with dupilumab, which is not something we would necessarily expect, but it might be something worth trying in some of these tough management cases.

HCPLive: What is your central principle in evaluating whether you are going to try a new medication?

 One of the central principles I use in evaluating whether I'm going to try a new medication is what’s our experience in children in other diseases? Because we can have a lot of safety data even if we don't have data about a specific illness. In many conditions we borrow—for example, other biologic agents—pediatric rheumatologists or gastroenterologists will be using drugs like Humira long before we do. They have a lot of safety data in children, and we can borrow from them and say, ‘well, this is the experience in children that's already been looked at, even if it's not for the condition we're treating.’

That's one of the ways that, as pediatric dermatologists, we try to extrapolate whether or not it's worth taking the risk [or] whether the benefit might outweigh the risk for very difficult cases.

Butera A. FDA Approves Dupilumab as Add-On for Youngest Atopic Dermatitis Patients. HCPLive. Published on June 7, 2022. Accessed June 26, 2026.

Pediatric Dermatology Update 2026. Session presented at the Maui Derm Summer 2026 meeting in Colorado Springs on June 26.

Articles

Dupilumab is FDA-approved for pediatric atopic dermatitis down to 6 months and for chronic spontaneous urticaria in patients ≥12 years, yet mounting pediatric dermatology experience supports broader off-label exploration. Reported benefits span intensely pruritic, inflammatory, and rare genodermatoses, sometimes with life-altering itch reduction. Despite its relatively narrow IL-4/IL-13 blockade, clinical responses have been observed in conditions with unclear pathobiology. Off-label decision-making is guided by disease severity, therapeutic need, and extrapolated pediatric safety data from other specialties’ biologic use.

Frieden on expanding dupilumab use in pediatric skin conditions: prurigo nodularis, EB pruriginosa, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Expanding Use of Dupilumab in Pediatric Patients, With Ilona Frieden, MD

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include the US Food and Drug Administration’s Complete Response Letter (CRL) for cytisinicline for treating nicotine dependence, phase 3 data for tulisokibart in ulcerative colitis, phase 2 data for CX11 in 

, the FDA approval of olezarsen (Tryngolza) for severe hypertriglyceridemia, and a 5-part special report recapping Obesity Medicine Association (OMA) news and updates.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of June 21, 2026 — let's jump in!

FDA Issues CRL for Cytisinicline NDA for Smoking Cessation

On June 22, 2026, the FDA issued a CRL to Achieve Life Sciences’ New Drug Application for cytisinicline as a treatment for nicotine dependence, citing manufacturing-related observations from an FDA current good manufacturing practice inspection of a third-party facility and incomplete final product labeling by the action date. Of note, no clinical efficacy or safety deficiencies were identified by the Agency.

Achieve said it had already partnered with US-based Adare Pharma Solutions as its new primary commercial manufacturing partner.

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A

On June 22, 2026, Merck announced topline results from the phase 3 ATLAS-UC induction-only study of tulisokibart (MK-7240) in patients with moderately to severely active UC, making it the first anti-TL1A monoclonal antibody to demonstrate clinical remission at week 12 in a phase 3 trial for this indication. In addition to meeting its primary endpoint, tulisokibart achieved key secondary endpoints and demonstrated a safety profile consistent with previous phase 2 studies.

CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports

On June 23, 2026, Corxel Pharmaceuticals reported positive topline findings from a phase 2 trial of CX11 in adults with obesity or overweight with ≥1 weight-related comorbidity. The Company said the trial met its primary endpoints and reported weight loss of up to 11.5% at 36 weeks.

“We are delighted with these positive U.S. Phase 2 results, which are consistent with the competitive profile established in the China Phase 3 program,” Bo Liang, MD, PhD, chief medical officer of Corxel, said in a statement. “Together, these datasets reinforce our confidence in CX11 and our conviction to offer patients around the world an effective and highly tolerable option with dosing flexibility.”

FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia

On June 24, 2026, the FDA approved olezarsen (Tryngolza; Ionis Pharmaceuticals) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG; triglycerides ≥500 mg/dL). The approval, which arrived ahead of the June 30, 2026 PDUFA date, makes olezarsen the first therapy approved specifically to reduce acute pancreatitis risk in sHTG.

Advancements and Insights from the Obesity Medicine Association Conference 2026

In this 5-part series, Raghuveer Vedala, MD, and Shagun Bindlish, MD, discuss the most impactful news from and key clinician insights on the Obesity Medicine Association (OMA) Annual Conference 2026, including stigmatization, pharmacotherapy updates, the expanding reach of GLP-1s, and more.

FDA issued a Complete Response Letter for cytisinicline in nicotine dependence driven by third-party cGMP manufacturing observations and incomplete labeling, without citing efficacy or safety deficits; Achieve aligned with Adare for US commercial supply. Merck reported phase 3 induction data showing tulisokibart, an anti-TL1A mAb, achieved week-12 clinical remission and key secondary endpoints in moderate-to-severe ulcerative colitis. Corxel’s phase 2 CX11 produced up to 11.5% weight loss at 36 weeks. FDA approved olezarsen for severe hypertriglyceridemia to lower pancreatitis risk. OMA updates emphasized stigma, GLP-1 expansion, and pharmacotherapy.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

The HCPFive: Top News for Healthcare Providers from the Week of 06/21

When the Allergen Is Not What You Expected: 2 Contact Dermatitis Cases

diagnosis often requires looking past the most obvious allergen source, according to Matthew Zirwas, MD, of Bexley Dermatology, who presented a case-based session at 

, Zirwas walked through 2 cases that illustrate how comprehensive patch testing reveals unexpected drivers and guides management when standard therapies have stalled.

 Paraphenylenediamine in an Automotive Factory Worker

The first case involved a patient with hand eczema working in an automotive factory who had not responded adequately to topical therapy. Comprehensive patch testing returned positive for roughly half a dozen allergens, but 1 stood out as the likely driver: paraphenylenediamine (PPD).

PPD is most commonly recognized as a hair dye allergen, but it is also used in the production of rubbers, plastics, automotive components, and industrial products.

 In this patient's case, a PPD-related compound was present in the lubricant used on factory parts, and the patient's gloves had become saturated with it, creating prolonged occlusive contact with the allergen.

"That gave us the answer in that one," Zirwas said.

Facial Dermatitis Persisting After CSU Treatment

The second case centered on a woman with chronic spontaneous urticaria (CSU) who had been started on antihistamines and subsequently remibrutinib, a BTK inhibitor. Nearly all of her disease cleared except for a persistent facial dermatitis with a mildly urticarial quality that did not present purely as hives.

Patch testing identified sensitization to multiple allergens, including fragrance, acrylates, gold, and nickel. She was enrolled in the contact allergen management program, a structured resource helping patients identify safe products based on their specific sensitization profile, and her facial dermatitis resolved. The precise culprit among the positive allergens was never definitively identified.

"We don't know which of those allergens ended up being the thing, whether it was the fragrance or the acrylates from nails or gold," Zirwas said. "To some extent we don't care. What we care about is that she’s better.”

Both cases reflect a broader clinical evolution Zirwas described across his session. He now positions patch testing as a later step rather than a first-line tool, reserving it for patients who have not responded to empiric avoidance and an IL-13 inhibitor trial. When the distinction between allergic contact dermatitis and atopic dermatitis remains unresolved, he said a biologic trial can itself clarify the diagnosis, since biologics do not meaningfully help isolated allergic contact dermatitis. For patients where getting them better takes priority over resolving the diagnostic question, he prefers a JAK inhibitor, which he said works regardless of which condition is driving the disease.

He also identified nickel and ammonium persulfate as the 2 allergens most frequently missed in routine eczematous workups, noting that dietary nickel and hot tub exposure, respectively, are the sources clinicians are most likely to overlook.

In earlier parts of this interview, Zirwas discussed using 

IL-13 inhibitor response to guide patch testing decisions in eczematous dermatitis

delgocitinib fills a long-standing gap in chronic hand eczema treatment

overlapping allergic contact dermatitis changes his biologic or JAK inhibitor selection approach

Editor’s note: Reported disclosures for Zirwas include GENZYME CORPORATION, Regeneron Healthcare Solutions, Dermavant Sciences, and more.

Zirwas M. Eczematous and Contact Dermatitis: Cases That Will Leave You Scratching Your Head. Session presented at Maui Derm Summer 2026 in Colorado Springs on June 24.

Mukkanna KS, Stone NM, Ingram JR. Para-phenylenediamine allergy: current perspectives on diagnosis and management. 

Mao T, Liu W, Deng J, et al. p-Phenylenediamines and p-phenylenediamine quinone derivatives in rubber consumer products and typical urban dust: Sources, transformation profiles, and health risks. 

Videos

At Maui Derm NP+PA Summer 2026, Matthew Zirwas, MD, shares cases of a factory worker with PPD allergy and a chronic spontaneous urticaria patient with persistent facial dermatitis.

When the Allergen Is Not What You Expected: 2 Contact Dermatitis Cases 

Interstitial Lung Abnormalities: Recognition, Risk Stratification, and When to Act

An interstitial lung abnormality (ILA) discovered incidentally on chest CT can be a difficult finding to communicate: the patient feels well, nothing requires immediate treatment, and yet the discovery carries real prognostic weight. Between 20% and 60% of ILAs progress to interstitial lung disease (ILD) over 2 to 5 years — making early recognition and structured follow-up important, and making the absence of a standardized management framework a genuine clinical problem.1 That framework arrived in May 2025, when the American Thoracic Society published its first formal clinical practice guidelines on ILA evaluation and management.2

Jessica Glennie, MSN, APRN, of the Cleveland Clinic ILD Center in Cleveland, Ohio, addressed ILAs in her session at APAP 2026, calling the findings "almost like the origin story of interstitial lung disease."1 She described the new ATS guidelines as a meaningful improvement over prior Fleischner Society guidance — providing more granular direction on monitoring intervals, biomarker testing, and which patient subgroups warrant closer surveillance.

One of the more clinically consequential changes in the 2025 ATS guidelines is the reclassification of high-risk populations, including patients with connective tissue diseases such as rheumatoid arthritis and scleroderma. Previously, these patients were excluded from ILA classification because their findings were considered attributable to known underlying disease. The new guidelines permit an ILA designation in these patients, with the recognition that they carry elevated progression risk and require more intensive monitoring — a change Glennie called important for guiding follow-up in patients she routinely sees in the ILD clinic.2

For APPs encountering an ILA for the first time on a scan, she emphasized risk factor management as a unifying priority regardless of ILA subtype: smoking cessation, vaccination to reduce the risk of pneumonia and respiratory infections that can accelerate progression, and optimization of any underlying rheumatologic disease in coordination with rheumatology. Monitoring frequency — CT scans and pulmonary function testing — should be guided by whether the ILA has fibrotic features and other risk factors for progression per the ATS framework.2

Counseling the patient who feels well and is surprised by the finding requires calibration. Glennie described her approach as honest about the range of outcomes — many ILAs do not progress — while being clear that some do, and that the goal of surveillance is to catch progression early and intervene before function declines. "You sit down with that patient and explain what we find, talk about those percentages of patients that can progress, and then make sure that any risk factors they have are managed," she said. "It's usually a good discussion of preventative medicine."

Integration of the new guidelines into practice is still lagging, she acknowledged — a predictable dynamic for guidance released less than a year ago — but she anticipates their adoption will accelerate as APPs and other clinicians become more familiar with the updated framework.

Glennie J. ILAs. Presented at: APAPP National Conference 2026, June 18-20; Las Vegas, NV.

Raghu G, Remy-Jardin M, Richeldi L, et al. Approach to the evaluation and management of interstitial lung abnormalities: an official ATS clinical practice guideline. 

Jessica Glennie, MSN, APRN, says the first formal ATS clinical guidelines on interstitial lung abnormalities are filling a real gap — but integration into practice is still catching up.


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Larence Leiter, MD, is the director of the Lipid Clinic and associate director of the Clinical Nutrition and Risk Factor Modification centre at St. Michael’s Hospital in Toronto.

Lawrence Leiter, MD | Image Credit: University of Toronto

Intensive LDL-C lowering has reshaped secondary prevention over the past decade, with large randomized trials consistently demonstrating incremental cardiovascular benefit as achieved 

 falls below previously accepted thresholds. The FOURIER trial enrolled 27,564 patients with established 

atherosclerotic cardiovascular disease (ASCVD)

 on background statin therapy and randomized them to the PCSK9 inhibitor evolocumab or placebo, reducing median LDL-C to 30 mg/dL and reducing the risk of major adverse cardiovascular events. Long-term follow-up data from FOURIER-OLE, extending some patients' exposure to nearly 8 years, showed sustained event reduction including, for the first time with this drug class, a significant reduction in cardiovascular death.

The evidence now points toward earlier, more aggressive intervention. A 2024 meta-analysis of 60 randomized controlled trials found the hazard ratio per 1 mmol/L LDL-C reduction was more favorable in primary prevention (0.74) than in secondary prevention (0.80), suggesting greater proportional event reduction is achievable before atherosclerotic burden accumulates. For patients with 

, the risk calculus is further complicated by persistent residual cardiovascular risk: the ADA's 2026 Standards of Care reaffirm LDL-C lowering as central to ASCVD risk reduction in this population, with benefit directly proportional to the magnitude of LDL-C reduction across statin and nonstatin regimens.

Lawrence A. Leiter, MD, director of the Lipid Clinic and associate director of the Clinical Nutrition and Risk Factor Modification Centre at St. Michael's Hospital in Toronto, has contributed to multiple FOURIER analyses and brings particular expertise to the intersection of lipid management and diabetes. In the following interview, Lawrence A. Leiter, MD, spoke with HCPLive at the 

 in Philadelphia about LDL-C target achievement, sequencing of nonstatin therapies, and multifactorial risk reduction in patients with diabetes.

Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD

HCPLive: In high-risk patients with diabetes who do not have established ASCVD, what defines the threshold for moving to PCSK9 inhibition rather than intensifying conventional lipid-lowering therapy?

I think the key point, what the evidence shows us, is that intensive LDL lowering and getting to targets lower than had been previously recommended is associated with significant cardiovascular benefit. The training, the VESALIUS-CV trial I was involved with, we used a PCSK9 inhibitor, evolocumab, in patients who had elevated LDL, despite optimized statin therapy. But when we translate in the real world, I think the key is the achievement of a lower LDL target, not the drugs that were specifically used. If patients aren't starting off with as high LDL as we had in VESALIUS-CV, often one can get them to a target of <55 or 40, as we did in the trial mix per deciliter with statins plus or minus ezetimibe plus or minus bempedoic acid, and only if you don't get them there with those agents, is it necessary to move on to a PCSK9 inhibitor?

HCPLive: Do you see the expanding use of PCSK9 inhibition in high-risk diabetes as a shift towards preemptive ASCVD disease modification?

Well, I think we know it's easier to prevent disease than it is to treat it when it's already present. First of all, looking at the big picture, there are far too many patients we see whose first symptom is their last symptom. Patients who had unrecognized atherosclerosis have an MI and may pass away as a result of that. We cannot wait until people have significant atherosclerotic burden and only start to treat then – we need to prevent it earlier. I think we now know that for the same magnitude of LDL cholesterol reduction you're going to see greater event reduction in people who have not yet had an event, so-called primary prevention population, than those who already did. That's presumably because it's easier to prevent plaque from occurring rather than waiting until a person has significant plaque in their coronary arteries and only then intervening.

HCPLive: Are we approaching a point in which lipid lowering in diabetes is viewed as a foundational risk reprogramming?

Well, our patients with diabetes continue to have increased cardiovascular risk, and even the latest data would show that our patients with diabetes continue to have twice the cardiovascular risk as people without diabetes, and there isn't going to be a single intervention that is going to reduce that risk. We really need a multifactorial risk reduction strategy. It's difficult, and patients will push back against polypharmacy, and often it's a negotiation for each additional drug we need to add. But to me, optimizing all the risk factors is foundational. We have to improve their glucose, improve blood pressure, optimize lipids, use other evidence-based therapies, SGLT2 inhibitors, GLP-1 RAs, aspirin as appropriate. There are many things we need to do to significantly reduce the risk in our patients with diabetes.

Editors’ Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. 

Brouwers JJWM, Koopal M, Visseren FLJ, et al. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 60 randomized controlled trials. Atherosclerosis. 2024;395:118540. 

doi:10.1016/j.atherosclerosis.2024.118540

American Diabetes Association. 10. Cardiovascular disease and risk management: standards of care in diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S216-S266. 

https://pubmed.ncbi.nlm.nih.gov/41358899/

Intensive LDL-C lowering to levels near 30 mg/dL with PCSK9 inhibition has delivered sustained MACE reductions and, with prolonged exposure, cardiovascular mortality benefit. Meta-analytic data indicate larger proportional risk reductions in primary versus secondary prevention, supporting earlier intervention before plaque burden accrues. In diabetes, persistent residual ASCVD risk makes LDL-C lowering a central, dose-responsive strategy across statin and nonstatin regimens. Practical sequencing emphasizes achieving stringent LDL-C targets (eg, <55 or <40 mg/dL) using statins, ezetimibe, and bempedoic acid before escalating to PCSK9 inhibitors.

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

Dyslipidemia

Type 1 Diabetes

Strategic Alliance Partnership

Oksana Hamidi, DO, is an associate professor in the division of endocrinology and metabolism at UT Southwestern Medical Center

In the final episode, ‘Integrating Hypercortisolism Screening into Clinical Practice,’ the panelists explore practical strategies for improving recognition, screening, and management of hypercortisolism in routine clinical care. 

Video Series

Integrating Hypercortisolism Screening into Clinical Practice

This episode, titled ‘Management Strategies for Hypercortisolism,’ features panelists discussing the practical considerations involved in long-term management of hypercortisolism and the importance of maintaining sustained disease control while minimizing treatment-related complications. 

Management Strategies for Hypercortisolism

In ‘Monitoring and Maintaining Long-Term Disease Control in Hypercortisolism,’ our panel explores how clinicians balance sustained cortisol control with the need to manage long-term metabolic risk in patients with hypercortisolism. 

Monitoring and Maintaining Long-Term Disease Control in Hypercortisolism

In this episode, ‘Long-Term Treatment Adherence and Persistence in Hypercortisolism,’ the panelists explore the factors that influence long-term treatment success and the challenges of maintaining adherence to medical therapy in patients with hypercortisolism. 

Long-Term Treatment Adherence and Persistence in Hypercortisolism

This episode, titled ‘Evaluating Clinical and Real-World Evidence in Hypercortisolism,’ features panelists discussing key clinical trial findings, real-world treatment experiences, and emerging research that continue to shape the management of hypercortisolism. The expert faculty review efficacy, safety, and practical considerations associated with several established therapies while also exploring new insights into the relationship between cortisol excess and metabolic dysfunction.

Evaluating Clinical and Real-World Evidence in Hypercortisolism

In ‘Emerging Clinical Evidence and Cardiometabolic Outcomes in Hypercortisolism,’ our panel explores recent clinical data evaluating the impact of available therapies on cortisol control, metabolic health, and long-term disease management. The expert faculty discuss findings from clinical trials and real-world studies that continue to shape treatment decisions in patients with hypercortisolism.

Emerging Clinical Evidence and Cardiometabolic Outcomes in Hypercortisolism 

In this episode, ‘Navigating Treatment Selection in Hypercortisolism,’ the expert endocrinologists explore available treatment options for hypercortisolism and discuss how clinicians individualize therapy based on disease etiology, severity, comorbidities, and long-term treatment goals. The panelists explain that while surgery remains the preferred approach when a removable source of cortisol excess is identified, medical therapy plays an important role for patients who are not immediate surgical candidates, require preoperative optimization, or need chronic disease management.

Navigating Treatment Selection in Hypercortisolism

This episode, titled ‘Pathophysiology of Hypercortisolism,’ features panelists examining the biological mechanisms through which excess cortisol contributes to metabolic dysfunction and cardiometabolic disease. The expert faculty discuss how chronic cortisol exposure affects multiple organ systems and drives many of the clinical manifestations commonly observed in patients with hypercortisolism.

Pathophysiology of Hypercortisolism

Lindsay Fourman, MD, is an endocrinologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School

Lindsay Fourman, MD, discusses early real-world data exploring the use of GLP-1 receptor agonists alongside metreleptin in lipodystrophy.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Synergy Between Metreleptin and GLP-1 Receptor Agonists in Lipodystrophy Real-World Data Suggest 

In ‘Clinical Impact of Hypercortisolism and Early Intervention,’ our panel explores the long-term consequences of sustained cortisol excess and discusses why timely diagnosis and treatment are critical for improving patient outcomes. The expert faculty examine how prolonged exposure to elevated cortisol levels contributes to progressive cardiometabolic dysfunction and increases the risk of serious complications across a broad spectrum of patients with hypercortisolism.

Latest News

Expanding Use of Dupilumab in Pediatric Patients, With Ilona Frieden, MD

The HCPFive: Top News for Healthcare Providers from the Week of 06/21

When the Allergen Is Not What You Expected: 2 Contact Dermatitis Cases

Interstitial Lung Abnormalities: Recognition, Risk Stratification, and When to Act

Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD